Burst Biologics' umbilical cord blood-derived product is a promising option for spinal fusion, study finds

Biologics

Cytokines present in umbilical cord blood-derived products can stimulate cellular processes necessary for bone regeneration, according to a study in Regenerative Medicine.

Burst Biologics researchers evaluated BioBurst Fluid, a cryopreserved umbilical cord blood-derived cellular allograft that is rich in growth factors, as well as cytokines and cells.

Researchers profiled UCB product from 33 donors to identify 44 quantifiable cytokines. They found UCB products elevated the proliferation and migration rates of mesenchymal stem cells and bone marrow stromal cells.

Additionally, researchers observed UCB product-induced secretion of Vegf-A, which promotes angiogenesis of endothelial cells, and osteoprotegerin, which promotes osteogenic differentiation of MSCs

Study authors conclude BioBurst Fluid is, "an excellent candidate for potential applications in orthopedic procedures like bone non-union and spinal fusion."

The study accompanies two ongoing clinical trials of BioBurst Fluid for bone consolidation in spine as well as foot and ankle fusions.

Here is Burst Biologics' spinal fusion registry, and here is the company's foot and ankle registry.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers